Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents.

Next Previous
Trial Profile

TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naproxen sodium/sumatriptan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 15 May 2015 According to a Pernix Therapeutics Holdings media release, the U.S. FDA has approved Treximet for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.
  • 01 May 2015 According to a Pernix Therapeutics Holdings media release, Treximet was granted pediatric exclusivity by the FDA, which will extend U.S. market exclusivity associated with the Orange Book listing for Treximet s patents by an additional six months.
  • 01 May 2015 According to a Pernix Therapeutics Holdings media release, sNDA for Treximet for use in adolescent patients for acute treatment of migraine has been accepted for filing with priority review; FDA action is expected by May 14, 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top